By contrast, for KEAP1/KRAS WT PDX models we detected no significant differences in tumor growth between the vehicle control and any of the three treatments (CsA, CB-839, or their combination) (Fig. 6G, Supplementary Fig. 11E, G and H). This evidence concerns the gene KRAS and neoplasm.